Form 4: Fulgent Genetics CEO Ming Hsieh Reports Stock Withholding

CEO Ming Hsieh reported the withholding of 4,392 shares of Fulgent Genetics common stock to satisfy tax obligations related to RSU vesting.

Summary

• Ming Hsieh, CEO of Fulgent Genetics, Inc., executed a transaction on June 1, 2026.
• 4,392 shares of common stock were withheld by the company to cover tax withholding obligations.
• The transaction occurred at a price of $18.09 per share.
• Following this transaction, Mr. Hsieh maintains direct ownership of 893,293 shares.
• Mr. Hsieh retains significant indirect ownership through various trusts and family accounts, totaling over 8.1 million shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a mandatory tax compliance action rather than a strategic shift or market-driven trade.

Positives

• The transaction was a routine tax withholding event rather than a discretionary open-market sale.
• The CEO maintains a substantial equity stake in the company, signaling continued alignment with shareholder interests.

Negatives

• The transaction results in a minor reduction of direct share ownership for the CEO.

Risks

• Concentration of ownership in trusts and family accounts may influence corporate governance decisions.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Management Comments

• The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units.

Industry Context

StockSavvy.ai notes that routine tax withholding filings by executives are standard corporate practice and generally do not reflect a change in management sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The filing follows standard SEC reporting requirements for executive compensation and tax compliance.
• The structure of ownership through trusts is common among founders and high-net-worth executives in the biotechnology sector.

Related Party Transactions

• The filing discloses holdings through The Ming Hsieh Trust, the Dynasty Trust, and family accounts, which are standard for the reporting person's estate planning.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a non-discretionary tax settlement.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Fulgent Genetics, FLGT, Insider Trading, Form 4, Ming Hsieh, Equity Compensation